Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19
- 1 July 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 31 (7), 1384-1386
- https://doi.org/10.1681/ASN.2020050589
Abstract
No abstract availableFunding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (DK117014)
This publication has 13 references indexed in Scilit:
- Compassionate Use of Remdesivir for Patients with Severe Covid-19The New England Journal of Medicine, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsThe New England Journal of Medicine, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016
- Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyCritical Care, 2015
- Pharmacokinetics of sulfobutylether- -cyclodextrin (SBECD) in subjects on hemodialysisNephrology Dialysis Transplantation, 2011
- Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalitiesKidney International, 2010
- Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)Journal of Pharmaceutical Sciences, 2010